Cortexyme Inc

NASDAQ:CRTX   3:59:42 PM EDT
48.33
-1.09 (-2.21%)
Other Pre-Announcement

Cortexyme Reports Third Quarter 2020 Financial Results

Published: 11/12/2020 22:05 GMT
Cortexyme Inc (CRTX) - Cortexyme Announces Third Quarter 2020 Financial Results and Provides Business Update.
Q3 Loss per Share $0.73.
Q3 Earnings per Share Estimate $-0.62 -- Refinitiv Ibes Data (analyst estimates).
Cash, Cash Equivalents, and Short and Long-term Marketable Securities As of September 30, 2020, Were $197.9 Million.
Cortexyme - Expects Current Cash & Cash Equivalents Will Be Sufficient to Fund Operations Through 2022 and Completion of Gain Trial.
Cor588 Remains on Track With Ind-enabling Studies; Clinical Studies Are Expected to Begin in Q3 2021.